Use of a solid calcium compound in the fabrication of a hemostatic agent for reducing bleeding from a surgical site during and/or after a surgical treatment in a patient is provided, wherein the solid calcium compound is selected from the group consisting of calcium phosphate, calcium sulfate, calcium carbonate, calcium oxide, calcium hydroxide, hydroxyapatite, and a combination thereof.

Use of a solid calcium compound in the fabrication of a hemostatic agent for reducing bleeding from a surgical site during and/or after a surgical treatment in a patient is provided, wherein the solid calcium compound is selected from the group consisting of calcium phosphate, calcium sulfate, calcium carbonate, calcium oxide, calcium hydroxide, hydroxyapatite, and a combination thereof.

An aerosol spray device includes a container having first and second fluid reservoirs disposed therein that are divided from one another. The first fluid reservoir holds a first mixture including a first aerosol propellant and a first part of a silicone based topical skin adhesive that is dissolved in the first aerosol propellant. The second fluid reservoir holds a second mixture including a second aerosol propellant and a second part of the silicone based topical skin adhesive that is dissolved in the second aerosol propellant. An aerosol spray dispensing system is connected with the container, which is configured to combine the first and second mixtures to form the silicone based topical skin adhesive and dispense the silicone based topical skin adhesive from the container as an aerosol spray.

Described herein are fluid complex coacervates that produce solid adhesives in situ. Oppositely charged polyelectrolytes were designed to form fluid adhesive complex coacervates at ionic strengths higher than the ionic strength of the application site, but an insoluble adhesive solid or gel at the application site. When the fluid, high ionic strength adhesive complex coacervates are introduced into the lower ionic strength application site, the fluid complex coacervate is converted to a an adhesive solid or gel as the salt concentration in the complex coacervate equilibrates to the application site salt concentration. In one embodiment, the fluid complex coacervates are designed to solidify in situ at physiological ionic strength and have numerous medical applications. In other aspects, the fluid complex coacervates can be used in aqueous environment for non-medical applications.

Described herein are fluid complex coacervates that produce solid adhesives in situ. Oppositely charged polyelectrolytes were designed to form fluid adhesive complex coacervates at ionic strengths higher than the ionic strength of the application site, but an insoluble adhesive solid or gel at the application site. When the fluid, high ionic strength adhesive complex coacervates are introduced into the lower ionic strength application site, the fluid complex coacervate is converted to a an adhesive solid or gel as the salt concentration in the complex coacervate equilibrates to the application site salt concentration. In one embodiment, the fluid complex coacervates are designed to solidify in situ at physiological ionic strength and have numerous medical applications. In other aspects, the fluid complex coacervates can be used in aqueous environment for non-medical applications.

Disclosed herein are compounds of formula (I)

##STR00001##

and therapeutic methods of treatment with compounds of formula (I), wherein L.sup.1, L.sup.2, L.sup.4, R.sup.1, R.sup.4, R.sup.5, R.sup.6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

Disclosed herein are compounds of formula (I)

##STR00001##

and therapeutic methods of treatment with compounds of formula (I), wherein L.sup.1, L.sup.2, L.sup.4, R.sup.1, R.sup.4, R.sup.5, R.sup.6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

An adhesive wafer for an ostomy device, the wafer comprising a skin-facing adhesive layer, a backing layer on a part of the non-skin-facing side of the adhesive layer, and a hole for accommodating a stoma. On the central portion of the wafer is located a release layer being configured to release a neutralizer. The release layer is in direct contact with the adhesive layer. The neutralizer is capable of neutralizing or at least minimizing the level of skin or adhesive aggressiveness of the output.

An adhesive wafer for an ostomy device, the wafer comprising a skin-facing adhesive layer, a backing layer on a part of the non-skin-facing side of the adhesive layer, and a hole for accommodating a stoma. On the central portion of the wafer is located a release layer being configured to release a neutralizer. The release layer is in direct contact with the adhesive layer. The neutralizer is capable of neutralizing or at least minimizing the level of skin or adhesive aggressiveness of the output.

The present disclosure provides technology that can ensure excellent visibility when introducing an embolization agent and that reduces the visibility of said agent after introduction. Provided is an embolization agent having a hydrogel which contains a visualizing agent, and a reaction product of an ethylenically unsaturated monomer, a crosslinking agent, and, as necessary, a bifunctional monomer, where the swelling ratio of the embolization agent is 5-300 times, and the post-swelling CT number of the embolization agent is 50-300 HU and falls below the pre-swelling CT number of the embolization agent.